Keywords: leukemia fungal infections voriconazole azole Kang.

        The researchers pointed out that the leukemia patients in the dangerous period voriconazole azole Kang (Voriconazole), appears to be the prevention of fungal infection recurrence.

        Triazole antifungal voriconazole azole health can be effective against Aspergillus, Candida genera and stem cell transplant patients in some rare fungal infections (such as the Fusarium foot branch fungal genera). This drug can be taken orally or intravenously, studies have shown that as the main treatment is effective and well tolerated. However, previously infected with fungal chemotherapy leukemia, it may also be used as a secondary prevention. To determine this, the Department of Hematology, Henri Mondor Hospital in France Cordonnier (Catherine Cordonnier) and colleagues studied 11 patients with this drug (400 mg / day, orally or intravenously, 44-245 days, an average of 137 ± 57 days ) the leukemia person.

        All patients daily to check the side effects, and conventional biochemical tests (including blood count, biochemistry, liver test, the hospital at least a week check twice during the non-institutional once a week). 10 people previously infected with Aspergillus, a person infected with Candida species, nine people plan to line stem cell transplantation, and 2 people need to consolidate the treatment of acute leukemia.

        The authors report no one fungal infection recurrence, chemotherapy or transplantation except for one, the rest were to continue the original, no one died of chemotherapy-induced neutropenia disease, no severe side effects. During immunotherapy given cyclosporine no difficulties, and one abnormal liver test results to stop treatment (biopsy confirmed later with graft-versus-host disease-related), 1 temporary visual impairment, but can continue treatment.

        “Although our study is smaller, its conclusions still that voriconazole azole Kang as leukemia dangerous period, especially the secondary prevention of transplant period allows patients completed treatment in accordance with the established arrangements", the authors conclude, “but also need prospective trials to confirm these findings. “